Important Guide for Natural Compounds Inclusion in Precision Medicine
Abstract
(ISSN 2577-5790)
OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.1 weeks; Submission to Acceptance: 17.0 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Pharmacogenomics and Precision Medicine: Unraveling the Future of Personalized Therapy
Submission Deadline: December 15, 2025 (Open) Submit Now
Guest Editor
Ahmad R. Alsayed, PhD, Associate Professor
Therapeutics and Precision Medicine, Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan
Research Interests: microbiome dysbiosis; microbiome health; pharmacogenomics; drug development
About This Topic
Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, is at the forefront of modern medicine's transition towards precision and personalized therapies. Recent advancements in genomic technologies and innovative computational approaches have enabled us to unravel the complex interplay between genetic variations, drug metabolism, and treatment outcomes. This special issue aims to showcase the latest breakthroughs in pharmacogenomics research, emphasizing its pivotal role in shaping the landscape of precision medicine.
We invite researchers and clinicians to contribute their original research, reviews, and perspectives on various dimensions of pharmacogenomics and its applications in precision medicine. Topics of interest include, but are not limited to:
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Important Guide for Natural Compounds Inclusion in Precision MedicineAbstract Precision medicine describes the definition of disease at a higher resolution by genomic and other technologies to enable more precise targeting of disease subgroups with new therapies. Preventative or therapeutic interventions can be developed with the knowledge of how a compound acts safely in the body to target receptors and produce the [...] |
Physico-Chemical Study of the Anti-Diabetic Drug of [BzN-EJJ-amide] for Treatment Type2 Diabetes Using CNT Sensor by Drug Delivery MethodAbstract The potential and selective inhibitors of protein tyrosine phosphatase 1B (PTP1B) are therapeutically useful in treating type 2 diabetes. N-Benzoyl-L-glutamyl-[4-phosphono(difluoromethyl)]-L-phenylalanine-[4-phosph [...] |
2023 | ||
CiteScore | SJR | SNIP |
0.4 | 0.160 | 0.093 |
TOP